Shuttle Pharmaceuticals Holdings, Inc., in conjunction with its subsidiary Shuttle Pharmaceuticals, Inc., is committed to the identification, advancement, and commercialization of pharmaceutical agents crafted to heighten the susceptibility of cancerous cells to radiation therapy. Its current portfolio of clinical-phase treatments features Ropidoxuridine, an orally administered halogenated pyrimidine, which is intended for individuals afflicted with brain tumors and soft tissue sarcomas. Additionally, the company is progressing Doranidazole, an injectable compound designed to make oxygen-deprived tumor cells more responsive to radiation, targeting malignancies of the pancreas, lungs, and liver. This enterprise was established in 2012 and maintains its principal operations in Rockville, Maryland.
Sector: Pharmaceutical Preparations
Industry: Drug Manufacturers - Specialty & Generic
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 4.76M shares outstanding
USShuttle Pharmaceuticals Holdings, Inc., in conjunction with its subsidiary Shuttle Pharmaceuticals, Inc., is committed to the identification, advancement, and commercialization of pharmaceutical agents crafted to heighten the susceptibility of cancerous cells to radiation therapy.
Its current portfolio of clinical-phase treatments features Ropidoxuridine, an orally administered halogenated pyrimidine, which is intended for individuals afflicted with brain tumors and soft tissue sarcomas.
Additionally, the company is progressing Doranidazole, an injectable compound designed to make oxygen-deprived tumor cells more responsive to radiation, targeting malignancies of the pancreas, lungs, and liver. This enterprise was established in 2012 and maintains its principal operations in Rockville, Maryland.
Adam Chambers
Director
Christopher Cooper
Interim Chief Executive Officer and Director
Michael Vander Hoek
Vice President for Operations and Regulatory
Christopher Robert Cooper
Interim CEO & Director
Employees
2
Country
US
Sector
--
Website
shuttlepharma.com
Loading congressional disclosures…
based on 4.76M shares outstanding
US30d Avg
45.05K
60d Avg
51.77K
90d Avg
1.07M
